Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07849231 |
| Title | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms (CLARITY-101) |
| Acronym | CLARITY-101 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Damora Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Site AU08 | NOT_YET_RECRUITING | Liverpool | New South Wales | 2170 | Australia | Details |
| Site AU09 | RECRUITING | Sydney | New South Wales | 2050 | Australia | Details |
| Site AU06 | NOT_YET_RECRUITING | Melbourne | Victoria | 2031 | Australia | Details |
| Site AU03 | NOT_YET_RECRUITING | Melbourne | Victoria | 3004 | Australia | Details |